source
- Pfizer's experimental eczema drug tilrekimig shows strong skin clearance in Phase 2 trialPfizer reported that its three‑pronged antibody, tilrekimig, met the primary endpoint of its Phase 2 study in patients with moderate to severe atopic dermatitis. After 16 weeks, a significantly hig…
- Lilly ends partnership with Foghorn after lead cancer drug fails efficacy testsLilly announced it is ending its collaboration with Foghorn Therapeutics after the biotech's lead cancer candidate, FHD-909, did not meet efficacy benchmarks in testing. The decision halts the join…